Analytical Data
-
Gene name
MPL
- Application
-
Alternative Names
MPL；TPOR；Thrombopoietin receptor
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P40238
-
Expression Region
26-491aa
-
AA Sequence
QDVSLLASDSEPLKCFSRTFEDLTCFWDEEEAAPSGTYQLLYAYPREKPRACPLSSQSMPHFGTRYVCQFPDQEEVRLFFPLHLWVKNVFLNQTRTQRVLFVDSVGLPAPPSIIKAMGGSQPGELQISWEEPAPEISDFLRYELRYGPRDPKNSTGPTVIQLIATETCCPALQRPHSASALDQSPCAQPTMPWQDGPKQTSPSREASALTAEGGSCLISGLQPGNSYWLQLRSEPDGISLGGSWGSWSLPVTVDLPGDAVALGLQCFTLDLKNVTCQWQQQDHASSQGFFYHSRARCCPRDRYPIWENCEEEEKTNPGLQTPQFSRCHFKSRNDSIIHILVEVTTAPGTVHSYLGSPFWIHQAVRLPTPNLHWREISSGHLELEWQHPSSWAAQETCYQLRYTGEGHQDWKVLEPPLGARGGTLELRPRSRYRLQLRARLNGPTYQGPWSSWSDPTRVETATETAW
-
Molecular Weight
56.5 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
MPL (myeloproliferative leukemia virus oncogene) is a critical receptor involved in hematopoiesis and the regulation of blood cell production. The study of MPL recombinant proteins has gained significant attention due to their potential implications in various hematological disorders, including thrombocytopenia and myeloproliferative neoplasms. Researchers have focused on understanding the structure and function of MPL, as its dysregulation can lead to abnormal blood cell development and disease. The recombinant form of MPL can be used in therapeutic applications, particularly in the enhancement of megakaryocyte differentiation and platelet production. Advances in biotechnology have allowed for the efficient expression and purification of MPL recombinant proteins, facilitating detailed studies of its signaling pathways and interactions with ligands such as thrombopoietin. Furthermore, the exploration of MPL as a target for drug development presents new avenues for treating disorders associated with its malfunction. This body of research is crucial not only for understanding basic biological processes but also for developing novel therapeutic interventions that can improve patient outcomes in blood-related diseases. In summary, MPL recombinant protein research is vital for elucidating the mechanisms of blood cell production and for advancing therapeutic strategies for myeloproliferative disorders.
